Effects of the sibutramine therapy on pulmonary artery pressure in obese patients

Guven A., Koksal N., Cetinkaya A., Sokmen G., Ozdemir R.

DIABETES OBESITY & METABOLISM, vol.6, no.1, pp.50-55, 2004 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 6 Issue: 1
  • Publication Date: 2004
  • Doi Number: 10.1111/j.1463-1326.2004.00314.x
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.50-55
  • Keywords: echocardiography, heart valves, pulmonary artery pressure, sibutramine, HYPERTENSION, TRIAL, FENFLURAMINE, EFFICACY, AGENTS, DRUGS, RISK
  • Bezmialem Vakıf University Affiliated: Yes


Aim: Obesity is a major global public health problem. Previous drugs (dexfenfluramine and fenfluramine) used for the treatment of obesity have been withdrawn due to various cardiac side effects. Sibutramine is an anti-obesity agent. The purpose of this study was to assess cardiac valve disease and pulmonary artery pressure (PAP) of the patients who used once daily doses of sibutramine.